CAR-T cells are patient T cells engineered to express a chimeric antigen receptor recognizing a tumor surface marker; on binding, they release cytotoxic granules that kill the tumor cell. Tumors often exploit checkpoint proteins (e.g. PD-1/PD-L1) to brake T cells — checkpoint inhibitors release that brake.
dT/dt = g*T - k_kill*E*T / (1 + brake)
dE/dt = prolif*E*T - decay*E
brake = 1 (checkpoint ON) or 0.15 (blockade ON)
- CAR-T dose — initial number/potency of engineered CAR-T cells infused.
- Tumor growth rate — intrinsic proliferation speed of the tumor cell cluster.
- Checkpoint blockade — toggling this removes the PD-1/PD-L1 "brake" that normally suppresses CAR-T killing efficiency.
Combining CAR-T therapy with checkpoint blockade is an active clinical strategy: CAR-T supplies the targeted attack while checkpoint inhibitors keep the attackers from being switched off by the tumor's defenses.